Literature DB >> 30726736

Bone Marrow Mesenchymal Stromal Cell-Derived Periostin Promotes B-ALL Progression by Modulating CCL2 in Leukemia Cells.

Zhenling Ma1, Xueli Zhao2, Mingjiao Deng2, Zhengjie Huang3, Jing Wang2, Yi Wu4, Dan Cui2, Yingfu Liu5, Rushi Liu6, Gaoliang Ouyang7.   

Abstract

Periostin (POSTN) is a multifunctional extracellular component that regulates cell-matrix interactions and cell-cell crosstalk. POSTN deletion significantly decreases leukemia burden in mice; however, the underlying mechanisms by which POSTN promotes B cell acute lymphoblastic leukemia (B-ALL) progression remain largely unknown. Here, we demonstrate that bone marrow (BM)-derived mesenchymal stromal cells (BM-MSCs) express higher levels of POSTN when co-cultured with B-ALL cells in vitro and in vivo. POSTN deficiency in BM-MSCs significantly decreases CCL2 expression in co-cultured B-ALL cells in vitro and in vivo. Moreover, POSTN treatment increases expression of CCL2 in B-ALL cells by activating the integrin-ILK-NF-κB pathway. Conversely, CCL2 treatment upregulates expression of POSTN in BM-MSCs via STAT3 activation. Furthermore, there is a positive correlation between POSTN expression and CCL2 level in the BM of mice and patients with B-ALL. These findings suggest that B-ALL cell-derived CCL2 contributes to the increased leukemia burden promoted by BM-MSC-derived POSTN.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B-ALL; CCL2; MSC; bone marrow; extracellular matrix; leukemia; matricellular protein; periostin

Mesh:

Substances:

Year:  2019        PMID: 30726736     DOI: 10.1016/j.celrep.2019.01.034

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  21 in total

Review 1.  Periostin: an emerging activator of multiple signaling pathways.

Authors:  Zhaoheng Wang; Jiangdong An; Daxue Zhu; Haiwei Chen; Aixin Lin; Jihe Kang; Wenzhao Liu; Xuewen Kang
Journal:  J Cell Commun Signal       Date:  2022-04-12       Impact factor: 5.782

Review 2.  The extracellular matrix of hematopoietic stem cell niches.

Authors:  Cornelia Lee-Thedieck; Peter Schertl; Gerd Klein
Journal:  Adv Drug Deliv Rev       Date:  2021-11-25       Impact factor: 15.470

Review 3.  In Vitro and In Vivo Modeling of Normal and Leukemic Bone Marrow Niches: Cellular Senescence Contribution to Leukemia Induction and Progression.

Authors:  Myriam Janeth Salazar-Terreros; Jean-Paul Vernot
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

4.  Engineering microparticles based on solidified stem cell secretome with an augmented pro-angiogenic factor portfolio for therapeutic angiogenesis.

Authors:  Thomas Später; Marisa Assunção; Kwok Keung Lit; Guidong Gong; Xiaoling Wang; Yi-Yun Chen; Ying Rao; Yucong Li; Chi Him Kendrick Yiu; Matthias W Laschke; Michael D Menger; Dan Wang; Rocky S Tuan; Kay-Hooi Khoo; Michael Raghunath; Junling Guo; Anna Blocki
Journal:  Bioact Mater       Date:  2022-04-02

5.  Reduced dynamic loads due to hip dislocation induce acetabular cartilage degeneration by IL-6 and MMP3 via the STAT3/periostin/NF-κB axis.

Authors:  Yutaka Nakamura; Mitsuru Saitou; Shingo Komura; Kazu Matsumoto; Hiroyasu Ogawa; Takaki Miyagawa; Takashi Saitou; Takeshi Imamura; Yuuki Imai; Hiroshi Takayanagi; Haruhiko Akiyama
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

Review 6.  The Bone Marrow Niche in B-Cell Acute Lymphoblastic Leukemia: The Role of Microenvironment from Pre-Leukemia to Overt Leukemia.

Authors:  Erica Dander; Chiara Palmi; Giovanna D'Amico; Giovanni Cazzaniga
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

7.  Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemia.

Authors:  Divij Verma; Costanza Zanetti; Parimala Sonika Godavarthy; Rahul Kumar; Valentina R Minciacchi; Jakob Pfeiffer; Markus Metzler; Sylvain Lefort; Véronique Maguer-Satta; Franck E Nicolini; Barbara Burroni; Michaela Fontenay; Daniela S Krause
Journal:  Leukemia       Date:  2020-01-09       Impact factor: 11.528

Review 8.  Targeting chemokines for acute lymphoblastic leukemia therapy.

Authors:  Zixi Hong; Zimeng Wei; Tian Xie; Lin Fu; Jiaxing Sun; Fuling Zhou; Muhammad Jamal; Qiuping Zhang; Liang Shao
Journal:  J Hematol Oncol       Date:  2021-03-20       Impact factor: 17.388

9.  Cytokines CCL2 and CXCL1 may be potential novel predictors of early bone loss.

Authors:  Yaqian Hu; Long Wang; Zhuojie Zhao; Weiguang Lu; Jing Fan; Bo Gao; Zhuojing Luo; Qiang Jie; Xiaojuan Shi; Liu Yang
Journal:  Mol Med Rep       Date:  2020-09-28       Impact factor: 2.952

10.  Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity.

Authors:  Samanta Romina Zanetti; Paola Alejandra Romecin; Meritxell Vinyoles; Manel Juan; José Luis Fuster; Mireia Cámos; Sergi Querol; Mario Delgado; Pablo Menendez
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.